Singapore's Prestige Biopharma inks MoU for co-development of COVID-19/Influenza vaccine

Retrieved on: 2022-03-30 06:45:23

Tags for this article:

Click the tags to see associated articles and topics

Singapore's Prestige Biopharma inks MoU for co-development of COVID-19/Influenza vaccine. View article details on hiswai:

Excerpt

Singapore-based Prestige Biopharma and Vaxine have entered into a memorandum of understanding (MoU) to collaborate on the supply of Vaxine's ...

Article found on: www.biospectrumasia.com